Journal of Drug Assessment Template
Write in a clean editor, then format for Journal of Drug Assessment in one click — DocuGuru applies the official Taylor & Francis template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
About the Journal of Drug Assessment format
Journal of Drug Assessment is a peer-reviewed journal published by Taylor & Francis, covering Medication Adherence and Compliance, Health Systems, Economic Evaluations, Quality of Life, Pharmaceutical studies and practices.
| Publisher | Taylor & Francis |
|---|---|
| Reference style | Author–year (Chicago, T&F) Author–year — (Smith, 2023) in the text Smith, Ada, Ben Jones, and Cara Lee. 2023. "A Representative Article Title." Journal of Drug Assessment 12 (3): 45–58.
Formats any DOI in Journal of Drug Assessment style. No sign-up. |
| Publishes research in | Medication Adherence and Compliance Health Systems, Economic Evaluations, Quality of Life Pharmaceutical studies and practices Pharmaceutical Practices and Patient Outcomes Pharmaceutical Economics and Policy |
| ISSN | 2155-6660 |
| h-index | 25 |
| i10-index | 62 |
| Total citations | 2,204 |
| Article processing charge | $969 |
| Top institutions publishing here | Hamad Medical Corporation |
| Journal website | www.tandfonline.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Papers published in Journal of Drug Assessment per year
Citation impact of Journal of Drug Assessment by publication year
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Most-cited papers in Journal of Drug Assessment
Atopic dermatitis (AD) is a chronic inflammatory disease persisting predominantly in the pediatric population. Its development is most presumably multifactorial and a derivative of interplay between genetic, immunologic, and environmental causes. To the authors' knowledge, no multinational and systematic database of AD prevalence is established and maintained for Europe. Thus, epidemiologic data originating from the…
Background: Spontaneous adverse drug reaction (ADR) reports prepared by healthcare professionals (HCPs) are the backbone of collecting post-marketing safety data. However, underreporting is a global problem creating health, economic, and ethical burden.Objectives: To determine the factors limiting ADR reporting rates from the HCPs’ point of view.Methods: A questionnaire containing 43 questions evaluating sociodemographic characteristics, pharmacovigilance…
OBJECTIVES: The long-acting muscarinic antagonist (LAMA) glycopyrronium (NVA237) has recently been approved as a once-daily treatment for COPD. The objectives of this study were to determine the dose delivery characteristics of glycopyrronium and compare them with those of the LAMA tiotropium, both delivered by their respective capsule-based dry-powder inhalers (DPIs). RESEARCH DESIGN AND METHODS: Seven…
Objective: This study aimed to translate the General Medication Adherence Scale (GMAS) into English language and validate it in patients suffering from chronic illnesses.Methods: A 1-month study (January 2018) was conducted in a random sample of patients suffering from chronic illnesses who visited the outpatient departments of four tertiary healthcare facilities in Karachi, Pakistan. Translation…